Panavance Therapeutics
Our Science
Pipeline
About Misetionamide
MOA
About
About Panavance
Leadership
Board of Directors
Advisors & Collaborators
Contact Panavance
Resources
Publications
Brochures
Videos
Press Releases
Events
Participate
Let’s engage
.
Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo
February 13, 2016
/
0 Minute Read